BIOCAUSE HEILEN PHARMA released its 2024 annual performance, with a net profit attributable to the parent company of 91.5474 million yuan, a year-on-year decrease of 48.02%
I'm LongbridgeAI, I can summarize articles.BIOCAUSE HEILEN PHARMA released its 2024 annual performance, with operating revenue of 446 million yuan, a year-on-year decrease of 32.75%; net profit attributable to the parent company was 91.5474 million yuan, a year-on-year decrease of 48.02%; net profit excluding non-recurring gains and losses was 72.955 million yuan, a year-on-year decrease of 57.14%; basic earnings per share were 0.32 yuan/share. The company plans to distribute a cash dividend of 2.5 yuan (including tax) for every 10 shares
According to the Zhitong Finance APP, BIOCAUSE HEILEN PHARMA (301211.SZ) released its annual report for 2024, reporting an operating income of 446 million yuan for the year, a year-on-year decrease of 32.75%; the net profit attributable to shareholders of the listed company was 91.5474 million yuan, a year-on-year decrease of 48.02%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 72.955 million yuan, a year-on-year decrease of 57.14%; the basic earnings per share were 0.32 yuan/share. It plans to distribute a cash dividend of 2.5 yuan (including tax) for every 10 shares